SEC Company Response from iBio, Inc. (IBIO) (CIK 0001420720) (IBIO) — Mar 19, 2020
iBio, Inc. (IBIO) (CIK 0001420720)
Date: March 19, 2020 · CIK: 0001420720 · Accession: 0001104659-20-035596
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-236735
Letter
March 19, 2020
VIA EDGAR
Mr. Joseph McCann, Legal Branch Chief
Mr. Paul Fischer, Staff Attorney
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: iBio, Inc.
Registration Statement on Form S-3
File No. 333-236735
Gentlemen:
Pursuant to Rule 461 promulgated under the Securities Act of 1933, as amended, iBio, Inc. (the “Registrant”) hereby requests acceleration of the effective date of its Registration Statement on Form S-3 (File No. 333-236735), as amended (the “Registration Statement”), so that it may become effective at 4:00 p.m. Eastern Daylight Time on March 19, 2020, or as soon as practicable thereafter.
If this request is granted, we respectfully request that we be notified by telephone at the time of effectiveness and that such effectiveness also be confirmed in writing. Please call Andrew Abramowitz of Andrew Abramowitz PLLC at 1 (212) 972-8882.
Best Regards,
iBio, Inc.
Show Raw Text
CORRESP
1
filename1.htm
March 19, 2020
VIA EDGAR
Mr. Joseph McCann, Legal Branch Chief
Mr. Paul Fischer, Staff Attorney
U.S. Securities and Exchange Commission
Division of Corporation Finance
Office of Life Sciences
100 F Street, N.E.
Washington, D.C. 20549
Re: iBio, Inc.
Registration Statement on Form S-3
File No. 333-236735
Gentlemen:
Pursuant to Rule 461 promulgated under
the Securities Act of 1933, as amended, iBio, Inc. (the “Registrant”) hereby requests acceleration of the effective
date of its Registration Statement on Form S-3 (File No. 333-236735), as amended (the “Registration Statement”), so
that it may become effective at 4:00 p.m. Eastern Daylight Time on March 19, 2020, or as soon as practicable thereafter.
If this request is granted, we respectfully
request that we be notified by telephone at the time of effectiveness and that such effectiveness also be confirmed in writing.
Please call Andrew Abramowitz of Andrew Abramowitz PLLC at 1 (212) 972-8882.
Best Regards,
iBio, Inc.
By:
/s/ Thomas F. Isett
Name: Thomas F. Isett
Title: Chief Executive Officer and Executive Co-Chairman